Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
‘Real life’ effectiviteit en veiligheid van SOF/VEL/VOX bij HCV na falen op DAA
nov 2019 | Hepatitis